Status:
COMPLETED
Rehabilitative Protocols in Progressive Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies
Lead Sponsor:
University of Pavia
Collaborating Sponsors:
University of Genova
Consorzio per Valutazioni Biologiche e Farmacologiche
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
25-65 years
Phase:
PHASE2
Brief Summary
Progressive multiple sclerosis (MS) patients have usually a worsening clinical course and it remains unclear if rehabilitation can indeed slow down the progression of the disease. Recently, clinical s...
Detailed Description
Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system that cause relevant disability, but also personal and familial suffering. Usually, after 10-15 years from th...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- age 25-65 years;
- right-handed
- progressive active form of MS treated with anti B monoclonal antibodies, Ocrelizumab or Rituximab since at least 6 months.
- EDSS 3-7.
- absence of relevant cognitive deficiency, as evaluated with Brief International Cognitive Assessment for MS (Bicams) °absence of visual or audio deficit disorders.
- Exclusion criteria:
- history of a cardiovascular disorder or any other disease that can hamper the active participation to the research project.
- Contraindication to perform MRI exams
Exclusion
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2024
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT06894940
Start Date
June 1 2021
End Date
November 30 2024
Last Update
March 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICS Salvatore Maugeri, Pavia
Pavia, Lombardy, Italy, 27100